top of page

Latest News

December 3, 2024

K36 Therapeutics Announces Multiple Poster Presentations Highlighting the First Clinical Data for KTX-1001 and Other Developmental Compounds at the 66th American Society of Hematology (ASH) Annual Meeting

December 4, 2023

K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

November 15, 2023

K36 Therapeutics Announces Appointment of Benjamin Winograd, MD, PhD, as Chief Medical Officer

Additional industry veterans recruited to strengthen clinical, translational medicine and preclinical teams.

Nov 8, 2023

K36 Therapeutics Named “Overall BioPharma Startup of the Year” 

Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry

Poster to be presented Sunday, December 10, 2023

Media Contact
info@k36tx.com

bottom of page